Pharsight

Cleviprex patents expiration

CLEVIPREX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103490 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(8 years from now)

US10010537 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(8 years from now)

US8658676 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(8 years from now)

Cleviprex is owned by Chiesi.

Cleviprex contains Clevidipine.

Cleviprex has a total of 3 drug patents out of which 0 drug patents have expired.

Cleviprex was authorised for market use on 01 August, 2008.

Cleviprex is available in emulsion;intravenous dosage forms.

The generics of Cleviprex are possible to be released after 10 October, 2031.

Drugs and Companies using CLEVIDIPINE ingredient

Market Authorisation Date: 01 August, 2008

Treatment: NA

Dosage: EMULSION;INTRAVENOUS

How can I launch a generic of CLEVIPREX before it's drug patent expiration?
More Information on Dosage

CLEVIPREX family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic